Back to blog

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

At the beginning of the week, shares of pharmaceutical giant AstraZeneca rose by 1.5%* on the London Stock Exchange. The reason? It was a reaction to the planned transfer of trading from Nasdaq via American Depositary Receipts directly to the New York Stock Exchange (NYSE). In response, investors in Europe began to wonder: “What would such a move mean for my portfolio?”

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

Harmonization

Chairman Michel Demare emphasized in an official statement that the new harmonized listing model is primarily intended to support the company’s long-term strategy of sustainable growth and access to global investors. The statement further noted that AstraZeneca remains firmly anchored in the United Kingdom—with its headquarters, tax residency, and primary listings in London and Stockholm. It can therefore be said that the transfer within the United States does not mean an escape from London but rather the company’s effort to expand its international investor base.

azn_ln

Source: Trading Economics*

London Under Pressure

The moves of major companies, however, evoke a broader trend. In recent years, London has faced a significant outflow of prestigious names—Unilever moved its activities to Amsterdam, while Glencore and Ashtead are considering similar steps. This is why news of a possible departure of AstraZeneca from London was perceived with concern. Based on current information, however, these concerns have been partially alleviated, though it is also clear that competition between stock exchanges is tougher than ever.

Political Dimension

The traditional political pressure from the U.S. is also not negligible. President Donald Trump repeatedly warned pharmaceutical companies that if they do not increase investment and production in the United States, they could face high tariffs. The move to list on the NYSE can therefore also be seen as a diplomatic gesture—a way to stay closer to U.S. investors and regulators without the company losing its European identity.

In addition, at the beginning of September the company decided to cancel its planned £200 million expansion of its research center in Cambridge, which at the same time signals that even in the United Kingdom the business environment is not without problems.

What Comes Next?

From a European investor’s perspective, AstraZeneca’s move to the NYSE is primarily about practical consequences. Expanding access to U.S. capital can support the company’s long-term growth, which may also be reflected in the performance of its shares on the London Stock Exchange. At the same time, however, this step is a reminder that London is no longer an automatic center for global companies, and the competitive pressure from the U.S. and the EU will continue to increase over time.[1]

*Past performance is not a guarantee of future results.

[1] Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. By their nature, forward-looking statements involve risk and uncertainty, as they relate to future events and circumstances that cannot be predicted, and actual developments and results may differ materially from those expressed or implied in any forward-looking statements.

Disclaimer! This marketing material is not and must not be understood as investment advice. Past performance is not a guarantee of future results. Investing in foreign currency may affect returns due to fluctuations. All securities transactions may result in both profits and losses. Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. CAPITAL MARKETS, o.c.p., a.s. is an entity regulated by the National Bank of Slovakia.

Sources:

https://www.investing.com/news/stock-market-news/astrazeneca-to-list-directly-on-nyse-while-keeping-uk-listing-shares-up-4259703
https://www.theguardian.com/business/2025/sep/29/astrazeneca-plans-new-york-stock-exchange-listing-but-isnt-quitting-london

Read more

Fintech Under Pressure: JPMorgan Introduces Paid Access to Client Data

Fintech Under Pressure: JPMorgan Introduces Paid Access to Client Data

In the heart of Manhattan, a relatively subtle yet crucial moment recently took place, which could redefine the future of the American financial sector. JPMorgan Chase, the largest American bank by assets and deposits, announced the conclusion of historic agreements with all the major fintech intermediaries behind most of the third-party data requests in the country.
Elon Musk and Tesla: The $1 Trillion Compensation Plan

Elon Musk and Tesla: The $1 Trillion Compensation Plan

On Thursday evening, at Tesla’s headquarters in Austin, excitement and tension filled the air. Tesla shareholders, at their annual general meeting, approved the largest compensation package in corporate history – nearly $1 trillion for Elon Musk. The measure, which sparked heated debate when introduced in September 2025, was ultimately passed with 75% shareholder support. But what exactly must Musk achieve to receive it?

Is SAP Europe’s winner in the field of artificial intelligence?

Is SAP Europe’s winner in the field of artificial intelligence?

SAP, a technology giant originating from Germany, is undergoing a key transformational stage in 2025. After years when its name was mainly associated with enterprise software, the company is increasingly positioning itself as a European leader in artificial intelligence and cloud computing. Although the results for the third quarter of 2025 slightly lagged behind expectations, the company’s long-term outlook encouraged investors.